GRACE PFEIFER: Open Payments
NPI 1184297558 · AMSTERDAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,761 in 59 payments from 12 companies in 2025. Trend: 2023 $759 · 2024 $1,182 · 2025 $1,761
Food & beverage: $1,761
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $507 |
| Teva Pharmaceuticals USA, Inc. | 10 | $278 |
| E.R. Squibb & Sons, L.L.C. | 2 | $231 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $229 |
| Axsome Therapeutics, Inc. | 3 | $168 |
| Neurocrine BioSciences, Inc. | 4 | $89 |
| Supernus Pharmaceuticals, Inc. | 3 | $66 |
| Janssen Pharmaceuticals, Inc | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Alkermes, Inc. | 2 | $41 |
Products named: VRAYLAR, COBENFY, CAPLYTA, UZEDY, Auvelity, INGREZZA, AUSTEDO XR, Qelbree.
Industry payments across NY — which companies pay providers there.
